FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Beat Thürlimann

Research Profile

Disorders

Procedures

Chemicals & Drugs

Physiology

Concepts & Ideas

Co-author Network

Publications

TOP 3
Markus Joerger; Beat Thürlimann
Chemotherapy regimens in early breast cancer: major controversies and future outlook.
Arnoud J Templeton; Beat Thürlimann; Madeleine Schwizer; Sarah Stoll; Michael Baumann; Daniel Dietrich; Michael Mark; Thomas Ruhstaller
Cross-sectional study of self-reported physical activity, eating habits and use of complementary medicine in breast cancer survivors.
Marianne Ewertz; John Forbes; Richard D Gelber; Aron Goldhirsch; Kathryn P Gray; István Láng; Hervé Bonnefoi; Alan S Coates; Marco Colleoni; Bent Ejlertsen; Robert Paridaens; Karen N Price; Manuela Rabaglio; Meredith M Regan; Ian E Smith; Beat Thürlimann; Henning T Mouridsen
Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Beat Thürlimann (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Markus Joerger; Beat Thürlimann
Chemotherapy regimens in early breast cancer: major controversies and future outlook.
Expert review of anticancer therapy 2013;13(2):165-78.
2013: Arnoud J Templeton; Beat Thürlimann; Madeleine Schwizer; Sarah Stoll; Michael Baumann; Daniel Dietrich; Michael Mark; Thomas Ruhstaller
Cross-sectional study of self-reported physical activity, eating habits and use of complementary medicine in breast cancer survivors.
BMC cancer 2013;13():153.
2012: Marianne Ewertz; John Forbes; Richard D Gelber; Aron Goldhirsch; Kathryn P Gray; István Láng; Hervé Bonnefoi; Alan S Coates; Marco Colleoni; Bent Ejlertsen; Robert Paridaens; Karen N Price; Manuela Rabaglio; Meredith M Regan; Ian E Smith; Beat Thürlimann; Henning T Mouridsen
Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(32):3967-75.
2012: Michael Mark; Beat Thürlimann
Fatal pneumonitis after treatment with pegylated liposomal doxorubicin in a patient with metastatic breast cancer in complete remission.
Medical oncology (Northwood, London, England) 2012;29(3):1477-8.
2012: Markus Joerger; Isabelle Konzelmann; Nicole Probst-Hensch; Anita Savidan; Beat Thürlimann; Christine Bouchardy; Harald Frick; Silvia Ess
A population-based study on the implementation of treatment recommendations for chemotherapy in early breast cancer.
Clinical breast cancer 2012;12(2):102-9.
2012: Meredith M Regan; Weining Tang; Beat Thürlimann; Giuseppe Viale; Maria Olivia Biasi; Mark Bouzyk; Alan Coates; Marc Debled; Patrizia Dell'Orto; Henrik J Ditzel; Richard D Gelber; Aron Goldhirsch; Roswitha Kammler; Brian Leyland-Jones; Maria B Lyng; Rudolf Maibach; Patrick Neven; Olivia Pagani; Karen N Price; James M Rae
CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial.
Journal of the National Cancer Institute 2012;104(6):441-51.
2012: Jacquie Chirgwin; Alan S Coates; Bent Ejlertsen; Aron Goldhirsch; Karen N Price; Meredith M Regan; Ian Smith; Zhuoxin Sun; Beat Thürlimann; Hervé Bonnefoi
The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause.
Breast cancer research and treatment 2012;131(1):295-306.
2011: Meredith M Regan; Ian Smith; Beat Thürlimann; Andrew Wardley; Alan Coates; Bent Ejlertsen; John Forbes; Richard D Gelber; Anita Giobbie-Hurder; Aron Goldhirsch; István Láng; Louis Mauriac; Patrick Neven; Karen N Price; Manuela Rabaglio
Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up.
The lancet oncology 2011;12(12):1101-8.
2011: Aron Goldhirsch; Hans-Jörg Senn; Beat Thürlimann; W C Wood; Alan Coates; Richard D Gelber
Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2011;22(8):1736-47.
2011: Marco Colleoni; Anita Giobbie-Hurder; Meredith M Regan; Beat Thürlimann; Henning Mouridsen; Louis Mauriac; John F Forbes; Robert Paridaens; István Láng; Ian Smith; Jacquie Chirgwin; Tadeusz Pienkowski; Andrew Wardley; Karen N Price; Richard D Gelber; Alan S Coates; Aron Goldhirsch
Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(9):1117-24.
2011: Kelly-Anne Phillips; Julie Aldridge; Karin Ribi; Zhuoxin Sun; Alastair Thompson; Vernon Harvey; Beat Thürlimann; Fatima Cardoso; Olivia Pagani; Alan S Coates; Aron Goldhirsch; Karen N Price; Richard D Gelber; Jürg Bernhard
Cognitive function in postmenopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trial.
Breast cancer research and treatment 2011;126(1):221-6.
2011: M Joerger; Beat Thürlimann; J Huober
Small HER2-positive, node-negative breast cancer: who should receive systemic adjuvant treatment?
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2011;22(1):17-23.
2010: Peter Brauchli; Beat Thürlimann; Susanne N Crowe; Richard Herrmann
What is the value of the 21-gene recurrence score?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(32):e671-2; author reply 673-4.
2010: Henning T Mouridsen; Per Lønning; Matthias W Beckmann; Kimberly Blackwell; Julie Doughty; Joseph GLIGOROV; Antonio Llombart-Cussac; Andre Robidoux; Beat Thürlimann; Michael Gnant
Use of aromatase inhibitors and bisphosphonates as an anticancer therapy in postmenopausal breast cancer.
Expert review of anticancer therapy 2010;10(11):1825-36.
2010: Kelly-Anne Phillips; Karin Ribi; Zhuoxin Sun; Alisa Stephens; Alastair Thompson; Vernon Harvey; Beat Thürlimann; Fatima Cardoso; Olivia Pagani; Alan S Coates; Aron Goldhirsch; Karen N Price; Richard D Gelber; Jürg Bernhard
Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomized trial.
Breast (Edinburgh, Scotland) 2010;19(5):388-95.
2010: Robert Paridaens; Shari Gelber; Bernard F Cole; Richard D Gelber; Beat Thürlimann; Karen N Price; Stig B Holmberg; Diana Crivellari; Alan Coates; Aron Goldhirsch
Adjuvant! Online estimation of chemotherapy effectiveness when added to ovarian function suppression plus tamoxifen for premenopausal women with estrogen-receptor-positive breast cancer.
Breast cancer research and treatment 2010;123(1):303-10.
2010: Jens Huober; Beat Thürlimann
Bone targeted therapy in breast cancer: present and future.
Critical reviews in oncology/hematology 2010;74 Suppl 1():S7-10.
2010: Nadia Harbeck; Gunter von Minckwitz; Beat Thürlimann
Bisphosphonates in adjuvant treatment of early breast cancer.
Critical reviews in oncology/hematology 2010;74 Suppl 1():S1.
2010: Roger von Moos; Clemens B Caspar; Rolf Steiner; Rahel Angst; Roman Inauen; Kerstin Schmieding; Beat Thürlimann
Long-term renal safety profile of ibandronate 6 mg infused over 15 minutes.
Onkologie 2010;33(8-9):447-50.
2010: Jens Huober; Otto Schoch; Arnoud Templeton; Christian Spirig; Beat Thürlimann
Interstitial pneumonitis after treatment with bevacizumab and pegylated liposomal doxorubicin in a patient with metastatic breast cancer.
Chemotherapy 2010;56(1):69-70.
2010: Janine Antonov; Vlad Popovici; Mauro Delorenzi; Pratyaksha Wirapati; Anna Baltzer; Andrea Oberli; Beat Thürlimann; Anita Giobbie-Hurder; Giuseppe Viale; Hans Jörg Altermatt; Stefan Aebi; Rolf Jaggi
Molecular risk assessment of BIG 1-98 participants by expression profiling using RNA from archival tissue.
BMC cancer 2010;10():37.
2009: Markus Joerger; Beat Thürlimann
Update of the BIG 1-98 Trial: where do we stand?
Breast (Edinburgh, Scotland) 2009;18 Suppl 3():S78-82.
2009: M Rabaglio; Z Sun; Karen N Price; Monica Castiglione-Gertsch; H Hawle; Beat Thürlimann; H Mouridsen; M Campone; J F Forbes; R J Paridaens; Marco Colleoni; T Pienkowski; J-M Nogaret; I Láng; I Smith; Richard D Gelber; Aron Goldhirsch; Alan Coates
Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2009;20(9):1489-98.
2009: Olivia Pagani; Karen N Price; Richard D Gelber; Monica Castiglione-Gertsch; Stig B Holmberg; Jurij Lindtner; Beat Thürlimann; John Collins; Martin F Fey; Alan Coates; Aron Goldhirsch
Patterns of recurrence of early breast cancer according to estrogen receptor status: a therapeutic target for a quarter of a century.
Breast cancer research and treatment 2009;117(2):319-24.
2009: Henning Mouridsen; Anita Giobbie-Hurder; Aron Goldhirsch; Beat Thürlimann; Robert Paridaens; Ian Smith; Louis Mauriac; John F Forbes; Karen N Price; Meredith M Regan; Richard D Gelber; Alan Coates
Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer.
The New England journal of medicine 2009;361(8):766-76.
2009: Aron Goldhirsch; J N Ingle; Richard D Gelber; Alan Coates; Beat Thürlimann; Hans-Jörg Senn
Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2009;20(8):1319-29.
2009: Olivia Pagani; Shari Gelber; Edda Simoncini; Monica Castiglione-Gertsch; Karen N Price; Richard D Gelber; Stig B Holmberg; Diana Crivellari; John Collins; Jurij Lindtner; Beat Thürlimann; Martin F Fey; Elizabeth Margaret Murray; John Forbes; Alan Coates; Aron Goldhirsch
Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93.
Breast cancer research and treatment 2009;116(3):491-500.
2008: Giuseppe Viale; Anita Giobbie-Hurder; Meredith M Regan; Alan Coates; Mauro Mastropasqua; Patrizia Dell'Orto; Eugenio Maiorano; gaetan macgrogan; Stephen G Braye; Christian Ohlschlegel; Patrick Neven; Orosz Zsolt; Wojciech P Olszewski; Fiona Knox; Beat Thürlimann; Karen N Price; Monica Castiglione-Gertsch; Richard D Gelber; Barry A Gusterson; Aron Goldhirsch
Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(34):5569-75.
2008: Roger von Moos; C B Caspar; Beat Thürlimann; R Angst; R Inauen; richard greil; B Bergstrom; K Schmieding; M Pecherstorfer
Renal safety profiles of ibandronate 6 mg infused over 15 and 60 min: a randomized, open-label study.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008;19(7):1266-70.
2008: Bernhard C Pestalozzi; David Zahrieh; Elizabeth Mallon; Barry A Gusterson; Karen N Price; Richard D Gelber; Stig B Holmberg; Jurij Lindtner; Raymond Snyder; Beat Thürlimann; Elizabeth Margaret Murray; Giuseppe Viale; Monica Castiglione-Gertsch; Alan Coates; Aron Goldhirsch
Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(18):3006-14.
2008: Diana Crivellari; Zhuoxin Sun; Alan Coates; Karen N Price; Beat Thürlimann; Henning Mouridsen; Louis Mauriac; John Forbes; Robert Paridaens; Monica Castiglione-Gertsch; Richard D Gelber; Marco Colleoni; István Láng; Lucia Del Mastro; Laurence Gladieff; Manuela Rabaglio; Ian E Smith; Jacquie H Chirgwin; Aron Goldhirsch
Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(12):1972-9.
2008: Christian Spirig; Beat Thürlimann; Jens Huober
[New treatment approaches in breast cancer].
Therapeutische Umschau. Revue thérapeutique 2008;65(4):207-10.
2008: Jens Huober; Beat Thürlimann
[Adjuvant endocrine therapy in breast cancer].
Therapeutische Umschau. Revue thérapeutique 2008;65(4):193-200.
2008: Alan Coates; Henning Mouridsen; Beat Thürlimann
Inappropriate ATAC on tamoxifen.
The lancet oncology 2008;9(4):315-6.
2008: Jürg Bernhard; David Zahrieh; J J Zhang; G Martinelli; R Basser; Christoph Hürny; John Forbes; Stefan Aebi; W Yeo; Beat Thürlimann; M D Green; Marco Colleoni; Richard D Gelber; Monica Castiglione-Gertsch; Karen N Price; Aron Goldhirsch; Alan Coates
Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer.
British journal of cancer 2008;98(1):25-33.
2008: Birgitte B Rasmussen; Meredith M Regan; Anne E Lykkesfeldt; Patrizia Dell'Orto; Barbara Del Curto; Katrine L Henriksen; Mauro Mastropasqua; Karen N Price; Eliane Méry; Magali Lacroix-Triki; Stephen Braye; Hans J Altermatt; Richard D Gelber; Monica Castiglione-Gertsch; Aron Goldhirsch; Barry A Gusterson; Beat Thürlimann; Alan Coates; Giuseppe Viale
Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial.
The lancet oncology 2008;9(1):23-8.
2007: Henning Mouridsen; Aparna Keshaviah; Alan Coates; Manuela Rabaglio; Monica Castiglione-Gertsch; Zhuoxin Sun; Beat Thürlimann; Louis Mauriac; John Forbes; Robert Paridaens; Richard D Gelber; Marco Colleoni; Ian Smith; Karen N Price; Aron Goldhirsch
Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(36):5715-22.
2007: K Ribi; Jürg Bernhard; Kaspar Rufibach; Beat Thürlimann; Roger von Moos; Thomas Ruhstaller; Agnes Glaus; Christel Böhme
Endocrine symptom assessment in women with breast cancer: what a simple "yes" means.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2007;15(12):1349-56.
2007: Giuseppe Viale; Meredith M Regan; Eugenio Maiorano; Mauro Mastropasqua; Patrizia Dell'Orto; Birgitte Bruun Rasmussen; Johnny Raffoul; Patrick Neven; Orosz Zsolt; Stephen Braye; Christian Ohlschlegel; Beat Thürlimann; Richard D Gelber; Monica Castiglione-Gertsch; Karen N Price; Aron Goldhirsch; Barry A Gusterson; Alan Coates
Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(25):3846-52.
2007: Aron Goldhirsch; William C Wood; Richard D Gelber; Alan Coates; Beat Thürlimann; Hans-Jörg Senn
Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2007;18(7):1133-44.
2007: Niels Seeholzer; Beat Thürlimann; Dieter Köberle; Dagmar Hess; Wolfgang C. Korte
Combining chemotherapy and low-molecular-weight heparin for the treatment of advanced breast cancer: results on clinical response, transforming growth factor-beta 1 and fibrin monomer in a phase II study.
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 2007;18(5):415-23.
2007: Per Karlsson; Bernard F Cole; Karen N Price; Alan Coates; Monica Castiglione-Gertsch; Barry A Gusterson; Elizabeth Margaret Murray; Jurij Lindtner; John P Collins; Stig B Holmberg; Martin F Fey; Beat Thürlimann; Diana Crivellari; John Forbes; Richard D Gelber; Aron Goldhirsch; Arne Wallgren
The role of the number of uninvolved lymph nodes in predicting locoregional recurrence in breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(15):2019-26.
2007: Louis Mauriac; Aparna Keshaviah; Marc Debled; Henning Mouridsen; John Forbes; Beat Thürlimann; Robert Paridaens; A Monnier; I Láng; Andrew Wardley; Jean-Marie Nogaret; Richard D Gelber; Monica Castiglione-Gertsch; Karen N Price; Alan Coates; Ian Smith; Giuseppe Viale; Manuela Rabaglio; N Zabaznyi; Aron Goldhirsch
Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2007;18(5):859-67.
2007: Aparna Keshaviah; Silvia Dellapasqua; N Rotmensz; Jurij Lindtner; Diana Crivellari; John Collins; Marco Colleoni; Beat Thürlimann; Caesar Mendiola; Stefan Aebi; Karen N Price; Olivia Pagani; Edda Simoncini; Monica Castiglione-Gertsch; Richard D Gelber; Alan Coates; Aron Goldhirsch
CA15-3 and alkaline phosphatase as predictors for breast cancer recurrence: a combined analysis of seven International Breast Cancer Study Group trials.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2007;18(4):701-8.
2007: Alan Coates; Aparna Keshaviah; Beat Thürlimann; Henning Mouridsen; Louis Mauriac; John Forbes; Robert Paridaens; Monica Castiglione-Gertsch; Richard D Gelber; Marco Colleoni; István Láng; Lucia Del Mastro; Ian Smith; Jacquie Chirgwin; Jean-Marie Nogaret; Tadeusz Pienkowski; Andrew Wardley; Erik H Jakobsen; Karen N Price; Aron Goldhirsch
Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(5):486-92.
2007: Jürg Bernhard; David Zahrieh; Monica Castiglione-Gertsch; Christoph Hürny; Richard D Gelber; John Forbes; Elizabeth Margaret Murray; John Collins; Stefan Aebi; Beat Thürlimann; Karen N Price; Aron Goldhirsch; Alan Coates
Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients--the International Breast Cancer Study Group Trial VIII.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(3):263-70.
2007: Lucien Perey; Robert Paridaens; H Hawle; K Zaman; F Nolé; Hans Wildiers; Maryse Fiche; D Dietrich; P Clément; Dieter Köberle; Aron Goldhirsch; Beat Thürlimann
Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00).
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2007;18(1):64-9.
2006: Aron Goldhirsch; Alan Coates; Richard D Gelber; JH Glick; Beat Thürlimann; Hans-Jörg Senn
First--select the target: better choice of adjuvant treatments for breast cancer patients.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006;17(12):1772-6.
2006: Thomas Ruhstaller; Helen Roe; Beat Thürlimann; Jonathan J Nicoll
The multidisciplinary meeting: An indispensable aid to communication between different specialities.
European journal of cancer (Oxford, England : 1990) 2006;42(15):2459-62.
2006: Agnes Glaus; Ch Boehme; Beat Thürlimann; Thomas Ruhstaller; Shu-Fang Hsu Schmitz; Rudolf Morant; Hans-Jörg Senn; Roger von Moos
Fatigue and menopausal symptoms in women with breast cancer undergoing hormonal cancer treatment.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006;17(5):801-6.
2006: Gregor Fürstenberger; Roger von Moos; Rudolf Lucas; Beat Thürlimann; Hans-Jörg Senn; Jürg Hamacher; Eva-Maria Boneberg
Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer.
British journal of cancer 2006;94(4):524-31.
2005: Beat Thürlimann; Aparna Keshaviah; Alan Coates; Henning Mouridsen; Louis Mauriac; John Forbes; Robert Paridaens; Monica Castiglione-Gertsch; Richard D Gelber; Manuela Rabaglio; Ian Smith; Andrew Wardley; Andrew Wardly; Karen N Price; Aron Goldhirsch
A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
The New England journal of medicine 2005;353(26):2747-57.
2005: Dieter Köberle; Beat Thürlimann
Adjuvant endocrine therapy in postmenopausal breast cancer patients.
Breast (Edinburgh, Scotland) 2005;14(6):446-51.
2005: Günther Gruber; Marco Bonetti; M Laura Nasi; Karen N Price; Monica Castiglione-Gertsch; Carl-Magnus Rudenstam; Stig B Holmberg; Jurij Lindtner; Rastko Golouh; John Collins; Diana Crivellari; Antonino Carbone; Beat Thürlimann; Edda Simoncini; Martin F Fey; Richard D Gelber; Alan Coates; Aron Goldhirsch
Prognostic value of extracapsular tumor spread for locoregional control in premenopausal patients with node-positive breast cancer treated with classical cyclophosphamide, methotrexate, and fluorouracil: long-term observations from International Breast Cancer Study Group Trial VI.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(28):7089-97.
2005: Aron Goldhirsch; JH Glick; Richard D Gelber; Alan Coates; Beat Thürlimann; Hans-Jörg Senn
Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16(10):1569-83.
2005: Olivia Pagani; Cristiana Sessa; Franco Nolè; Elisabetta Munzone; Diana Crivellari; D Lombardi; Beat Thürlimann; D Hess; Rossella Graffeo; M Ruggeri; S Longhi; Aron Goldhirsch
Dose-finding study of weekly docetaxel, anthracyclines plus fluoropyrimidines as first-line treatment in advanced breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16(10):1609-17.
2005: Beat Thürlimann; H J Senn
[Consensus Meeting of the 9th International Conference on Primary Therapy of Early Breast Cancer (St. Gall, January 26-29, 2005)].
Gynäkologisch-geburtshilfliche Rundschau 2005;45(3):143-6.
2005: Marco Colleoni; Sigui Li; Richard D Gelber; Alan Coates; Monica Castiglione-Gertsch; Karen N Price; Jurij Lindtner; Carl-Magnus Rudenstam; Diana Crivellari; John Collins; Olivia Pagani; Edda Simoncini; Beat Thürlimann; Elizabeth Margaret Murray; J Forbes; D Erzen; S Holmberg; Andrea Veronesi; Aron Goldhirsch
Timing of CMF chemotherapy in combination with tamoxifen in postmenopausal women with breast cancer: role of endocrine responsiveness of the tumor.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16(5):716-25.
2005: Marco Colleoni; David Zahrieh; Richard D Gelber; Stig B Holmberg; Jan E Mattsson; Carl-Magnus Rudenstam; Jurij Lindtner; Darja Erzen; Raymond Snyder; John Collins; Martin F Fey; Beat Thürlimann; Diana Crivellari; Elizabeth Margaret Murray; Caesar Mendiola; Olivia Pagani; Monica Castiglione-Gertsch; Alan Coates; Karen Price; Aron Goldhirsch
Site of primary tumor has a prognostic role in operable breast cancer: the international breast cancer study group experience.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(7):1390-400.
2004: D Hess; Beat Thürlimann; Olivia Pagani; Stefan Aebi; Daniel Rauch; Pierluigi Ballabeni; Beatrice Rufener; Monica Castiglione-Gertsch; Aron Goldhirsch
Capecitabine and vinorelbine in elderly patients (> or =65 years) with metastatic breast cancer: a phase I trial (SAKK 25/99).
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2004;15(12):1760-5.
2004: Jürg Bernhard; David Zahrieh; Alan Coates; Richard D Gelber; Monica Castiglione-Gertsch; Elizabeth Margaret Murray; John Forbes; Lucien Perey; John Collins; R Snyder; Carl-Magnus Rudenstam; Diana Crivellari; Andrea Veronesi; Beat Thürlimann; Martin F Fey; Karen N Price; Aron Goldhirsch; Christoph Hürny
Quantifying trade-offs: quality of life and quality-adjusted survival in a randomised trial of chemotherapy in postmenopausal patients with lymph node-negative breast cancer.
British journal of cancer 2004;91(11):1893-901.
2004: Marzio E E Sabbioni; Jürg Bernhard; Hans-Peter Siegrist; Shu-Fang Hsu Schmitz; Monica Castiglione Gertsch; Beat Thürlimann; Hervé Bonnefoi; Lucien Perey; Richard Herrmann; Aron Goldhirsch; Christoph Hürny
Does subjective burden of early breast cancer and its treatment affect immune measures during adjuvant therapy?
Breast cancer research and treatment 2004;87(1):75-86.
2004: Gilles Berclaz; Sigui Li; Karen N Price; Alan Coates; Monica Castiglione-Gertsch; Carl-Magnus Rudenstam; Stig B Holmberg; Jurij Lindtner; D Erien; John Collins; R Snyder; Beat Thürlimann; Martin F Fey; Caesar Mendiola; I Dudley Werner; Edda Simoncini; Diana Crivellari; Richard D Gelber; Aron Goldhirsch
Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2004;15(6):875-84.
2004: Beat Thürlimann; Dagmar Hess; Dieter Köberle; Isabella Senn; Pierluigi Ballabeni; Olivia Pagani; Lucien Perey; Stefan Aebi; Christoph Rochlitz; Aron Goldhirsch
Anastrozole ('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the double-blind cross-over SAKK trial 21/95--a sub-study of the TARGET (Tamoxifen or 'Arimidex' Randomized Group Efficacy and Tolerability) trial.
Breast cancer research and treatment 2004;85(3):247-54.
2004: Beat Thürlimann; A Müller; H-J Senn
Management of primary breast cancer: an update.
Onkologie 2004;27(2):175-9.
2003: H-J Senn; Beat Thürlimann; Aron Goldhirsch; William C Wood; Richard D Gelber; Alan Coates
Comments on the St. Gallen Consensus 2003 on the Primary Therapy of Early Breast Cancer.
Breast (Edinburgh, Scotland) 2003;12(6):569-82.
2003: Hans-Jörg Senn; Beat Thürlimann
The importance of evidence-based international consensus in the primary treatment of breast cancer--a periodic 'must'.
Breast (Edinburgh, Scotland) 2003;12(6):349-50.
2003: Aron Goldhirsch; William C Wood; Richard D Gelber; Alan Coates; Beat Thürlimann; Hans-Jörg Senn
Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(17):3357-65.
2003: Roger von Moos; Beat Thürlimann
Weekly paclitaxel (Taxol) with or without trastuzumab (Herceptin) in advanced breast cancer: a community-based observation study.
Onkologie 2003;26(2):128-32.
2003: Arne Wallgren; Marco Bonetti; Richard D Gelber; Aron Goldhirsch; Monica Castiglione-Gertsch; Stig B Holmberg; Jurij Lindtner; Beat Thürlimann; M Fey; I D Werner; John Forbes; Karen Price; Alan Coates; John Collins
Risk factors for locoregional recurrence among breast cancer patients: results from International Breast Cancer Study Group Trials I through VII.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(7):1205-13.
2002: Rudolf Morant; Shu-Fang Hsu Schmitz; Jürg Bernhard; Beat Thürlimann; Markus M Borner; Marion Wernli; Fritz Egli; P Forrer; A Streit; Emanuel Jacky; Silvia Hanselmann; J Bauer; Franz Hering; Hans-Peter Schmid
Vinorelbine in androgen-independent metastatic prostatic carcinoma--a phase II study.
European journal of cancer (Oxford, England : 1990) 2002;38(12):1626-32.
2002: Marco Colleoni; H J Litman; Monica Castiglione-Gertsch; Willi Sauerbrei; Richard D Gelber; Marco Bonetti; Alan Coates; M Schumacher; G Bastert; Carl-Magnus Rudenstam; Claudia Schmoor; Jurij Lindtner; John Collins; Beat Thürlimann; Stig B Holmberg; Diana Crivellari; C Beyerle; R L A Neumann; Aron Goldhirsch
Duration of adjuvant chemotherapy for breast cancer: a joint analysis of two randomised trials investigating three versus six courses of CMF.
British journal of cancer 2002;86(11):1705-14.
2002: Jürg Bernhard; Rudolf Maibach; Beat Thürlimann; C Sessa; Matti S Aapro
Patients' estimation of overall treatment burden: why not ask the obvious?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(1):65-72.
2001: Marco Colleoni; Shari Gelber; Alan Coates; Monica Castiglione-Gertsch; Richard D Gelber; Karen Price; Carl-Magnus Rudenstam; Jurij Lindtner; John Collins; Beat Thürlimann; Stig B Holmberg; H Cortes-Funes; Edda Simoncini; Elizabeth Margaret Murray; M Fey; Aron Goldhirsch
Influence of endocrine-related factors on response to perioperative chemotherapy for patients with node-negative breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(21):4141-9.
2001: Dieter Köberle; Beat Thürlimann
Anastrozole: pharmacological and clinical profile in postmenopausal women with breast cancer.
Expert review of anticancer therapy 2001;1(2):169-76.
2001: Diana Crivellari; Olivia Pagani; Andrea Veronesi; D Lombardi; Franco Nolè; Beat Thürlimann; D Hess; Markus M Borner; J Bauer; Giovanni Martinelli; Rossella Graffeo; Cristiana Sessa; Aron Goldhirsch
High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2001;12(3):353-6.
2000: Marco Colleoni; Anne O'Neill; Aron Goldhirsch; Richard D Gelber; Marco Bonetti; Beat Thürlimann; Karen N Price; Monica Castiglione-Gertsch; Alan Coates; Jurij Lindtner; John Collins; Hans-Jörg Senn; Franco Cavalli; J Forbes; A Gudgeon; Edda Simoncini; H Cortes-Funes; Andrea Veronesi; M Fey; Carl-Magnus Rudenstam
Identifying breast cancer patients at high risk for bone metastases.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(23):3925-35.
2000: Olivia Pagani; Cristiana Sessa; Franco Nolè; Diana Crivellari; D Lombardi; Beat Thürlimann; D Hess; Markus M Borner; J Bauer; Giovanni Martinelli; Rossella Graffeo; Massimo Zucchetti; Maurizio D'Incalci; Aron Goldhirsch
Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: a multicentric phase I-II study.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11(8):985-91.
2000: Stefan Aebi; Shari Gelber; Monica Castiglione-Gertsch; Richard D Gelber; John Collins; Beat Thürlimann; Carl-Magnus Rudenstam; Jurij Lindtner; Diana Crivellari; H Cortes-Funes; Edda Simoncini; I Dudley Werner; Alan Coates; Aron Goldhirsch
Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer?
Lancet 2000;355(9218):1869-74.
2000: Diana Crivellari; Marco Bonetti; Monica Castiglione-Gertsch; Richard D Gelber; Carl-Magnus Rudenstam; Beat Thürlimann; Karen N Price; Alan Coates; Christoph Hürny; Jürg Bernhard; Jurij Lindtner; John Collins; Hans-Jörg Senn; Franco Cavalli; J Forbes; A Gudgeon; Edda Simoncini; H Cortes-Funes; Andrea Veronesi; M Fey; Aron Goldhirsch
Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(7):1412-22.
2000: Marzio E E Sabbioni; Hans-Peter Siegrist; M Bacchi; Jürg Bernhard; Monica Castiglione; Beat Thürlimann; Hervé Bonnefoi; Lucien Perey; Richard Herrmann; Aron Goldhirsch; Christoph Hürny
Association between immunity and prognostic factors in early stage breast cancer patients before adjuvant treatment.
Breast cancer research and treatment 2000;59(3):279-87.
2000: Rudolf Morant; Jürg Bernhard; Rudolf Maibach; Markus M Borner; Martin F Fey; Beat Thürlimann; Emanuel Jacky; Felix B Trinkler; J Bauer; G Zulian; Silvia Hanselmann; Christoph Hürny; Franz Hering
Response and palliation in a phase II trial of gemcitabine in hormone-refractory metastatic prostatic carcinoma. Swiss Group for Clinical Cancer Research (SAKK).
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11(2):183-8.
2000: Marco Colleoni; Marco Bonetti; Alan Coates; Monica Castiglione-Gertsch; Richard D Gelber; Karen Price; Carl-Magnus Rudenstam; Jurij Lindtner; John Collins; Beat Thürlimann; S Holmberg; Andrea Veronesi; G Marini; Aron Goldhirsch
Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors. The International Breast Cancer Study Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(3):584-90.
1999: Jürg Bernhard; Beat Thürlimann; Shu-Fang Hsu Schmitz; Monica Castiglione-Gertsch; Franco Cavalli; Rudolf Morant; Martin F Fey; Hervé Bonnefoi; Aron Goldhirsch; Christoph Hürny
Defining clinical benefit in postmenopausal patients with breast cancer under second-line endocrine treatment: does quality of life matter?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(6):1672-9.
1999: Jürg Bernhard; Monica Castiglione-Gertsch; Shu-Fang Hsu Schmitz; Beat Thürlimann; Franco Cavalli; Rudolf Morant; Martin F Fey; Hervé Bonnefoi; Aron Goldhirsch; Christoph Hürny
Quality of life in postmenopausal patients with breast cancer after failure of tamoxifen: formestane versus megestrol acetate as second-line hormonal treatment. Swiss Group for Clinical Cancer Research (SAKK).
European journal of cancer (Oxford, England : 1990) 1999;35(6):913-20.
1999: Olivia Pagani; Cristiana Sessa; Giovanni Martinelli; Diana Crivellari; Angela Buonadonna; Beat Thürlimann; D Hess; Markus M Borner; J Bauer; Giulia Zampino; M Zimatore; Rossella Graffeo; A Riva; Aron Goldhirsch
Dose-finding study of epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(5):539-45.
1999: Marzio E E Sabbioni; Monica Castiglione; Christoph Hürny; Hans-Peter Siegrist; M Bacchi; Jürg Bernhard; Beat Thürlimann; Hervé Bonnefoi; Lucien Perey; Aron Goldhirsch; H J Senn
Interaction of tamoxifen with concurrent cytotoxic adjuvant treatment affects lymphocytes and lymphocyte subsets counts in breast cancer patients.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 1999;7(3):149-53.
1998: Marco Colleoni; Karen Price; Monica Castiglione-Gertsch; Aron Goldhirsch; Alan Coates; Jurij Lindtner; John Collins; Richard D Gelber; Beat Thürlimann; Carl-Magnus Rudenstam
Dose-response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancer. International Breast Cancer Study Group.
European journal of cancer (Oxford, England : 1990) 1998;34(11):1693-700.
1998: Jürg Bernhard; Christoph Hürny; Alan Coates; HF Peterson; Monica Castiglione-Gertsch; Richard D Gelber; E Galligioni; G Marini; Beat Thürlimann; John Forbes; Aron Goldhirsch; Hans-Jörg Senn; Carl-Magnus Rudenstam
Factors affecting baseline quality of life in two international adjuvant breast cancer trials. International Breast Cancer Study Group (IBCSG).
British journal of cancer 1998;78(5):686-93.
1998: Olivia Pagani; Anne O'Neill; Monica Castiglione; Richard D Gelber; Aron Goldhirsch; Carl-Magnus Rudenstam; Jurij Lindtner; John Collins; Diana Crivellari; Alan Coates; Franco Cavalli; Beat Thürlimann; Edda Simoncini; M Fey; Karen Price; Hans-Jörg Senn
Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI.
European journal of cancer (Oxford, England : 1990) 1998;34(5):632-40.
1998: Christoph Hürny; Brigitte van Wegberg; M Bacchi; Jürg Bernhard; Beat Thürlimann; O Real; Lucien Perey; Hervé Bonnefoi; A Coates
Subjective health estimations (SHE) in patients with advanced breast cancer: an adapted utility concept for clinical trials.
British journal of cancer 1998;77(6):985-91.
1997: Beat Thürlimann; Robert Paridaens; Daniel Serin; Jacques Bonneterre; Henri Roché; R Murray; E di Salle; S Lanzalone; MG Zurlo; G Piscitelli
Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: a phase II multicentre multinational study. Exemestane Study Group.
European journal of cancer (Oxford, England : 1990) 1997;33(11):1767-73.
1997: Aron Goldhirsch; Richard D Gelber; Monica Castiglione; Anne O'Neill; Beat Thürlimann; Carl-Magnus Rudenstam; Jurij Lindtner; John Collins; J Forbes; Diana Crivellari; Alan Coates; Franco Cavalli; Edda Simoncini; Martin F Fey; Olivia Pagani; Karen Price; Hans-Jörg Senn
Menstrual cycle and timing of breast surgery in premenopausal node-positive breast cancer: results of the International Breast Cancer Study Group (IBCSG) Trial VI.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1997;8(8):751-6.
1997: Beat Thürlimann; Monica Castiglione; Shu-Fang Hsu Schmitz; Franco Cavalli; Hervé Bonnefoi; Martin F Fey; Rudolf Morant; T Löhnert; Aron Goldhirsch
Formestane versus megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: a phase III prospective randomised cross over trial of second-line hormonal treatment (SAKK 20/90). Swiss Group for Clinical Cancer Research (SAKK)
European journal of cancer (Oxford, England : 1990) 1997;33(7):1017-24.
1997: Per Eystein Lønning; Robert Paridaens; Beat Thürlimann; G Piscitelli; E di Salle
Exemestane experience in breast cancer treatment.
The Journal of steroid biochemistry and molecular biology 1997;61(3-6):151-5.
1996: Beat Thürlimann; K Beretta; M Bacchi; Monica Castiglione-Gertsch; Aron Goldhirsch; W F Jungi; Franco Cavalli; Hans-Jörg Senn; M Fey; T Löhnert
First-line fadrozole HCI (CGS 16949A) versus tamoxifen in postmenopausal women with advanced breast cancer. Prospective randomised trial of the Swiss Group for Clinical Cancer Research SAKK 20/88.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1996;7(5):471-9.
1996: Martin Pecherstorfer; Zuzana Herrmann; Jean-Jacques Body; C Manegold; M Degardin; M R Clemens; Beat Thürlimann; M Tubiana-Hulin; E U Steinhauer; M van Eijkeren; H J Huss; D Thiébaud
Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(1):268-76.
1995: RA Joss; P Alberto; Christoph Hürny; M Bacchi; Serge Leyvraz; Beat Thürlimann; Thomas Cerny; G Martinelli; R Stahel; C Ludwig
Quality versus quantity of life in the treatment of patients with advanced small-cell lung cancer? A randomized phase III comparison of weekly carboplatin and teniposide versus cisplatin, adriamycin, etoposide alternating with cyclophosphamide, methotrexate, vincristine and lomustine. Swiss Group for Clinical Cancer Research (SAKK).
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1995;6(1):41-8.
1994: Markus M Borner; M Bacchi; Aron Goldhirsch; R Greiner; F Harder; Monica Castiglione; W F Jungi; Beat Thürlimann; Franco Cavalli; J P Obrecht
First isolated locoregional recurrence following mastectomy for breast cancer: results of a phase III multicenter study comparing systemic treatment with observation after excision and radiation. Swiss Group for Clinical Cancer Research.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(10):2071-7.
1994: RA Joss; M Bacchi; K Buser; V Kirchner; H Neuenschwander; B Orth; M S Aapro; Beat Thürlimann
Ondansetron plus dexamethasone is superior to ondansetron alone in the prevention of emesis in chemotherapy-naive and previously treated patients. Swiss Group for Clinical Cancer Research (SAKK).
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1994;5(3):253-8.
1994: Beat Thürlimann; Rudolf Morant; W F Jungi; A Radziwill
Pamidronate for pain control in patients with malignant osteolytic bone disease: a prospective dose-effect study.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 1994;2(1):61-5.
1994: Beat Thürlimann
Present status and potential role of high-dose adjuvant chemotherapy in breast cancer with poor prognosis.
Archives of gynecology and obstetrics 1994;255 Suppl 2():S379-80.
1992: Beat Thürlimann; R Waldburger; H J Senn; D Thiébaud
Plicamycin and pamidronate in symptomatic tumor-related hypercalcemia: a prospective randomized crossover trial.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1992;3(8):619-23.
1992: Beat Thürlimann; I Bachmann
Effective prevention of chemotherapy--induced phlebitis by low-dose heparin: a prospective randomised trial.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1992;3(4):311-3.
1991: Rudolf Morant; Beat Thürlimann; W F Jungi; L Schmid; E Holdener; U Schmid; Hans-Jörg Senn
[Peripheral spontaneous remission of hairy cell leukemia following transfusion-associated hepatitis C].
Schweizerische medizinische Wochenschrift 1991;121(10):344-6.
1991: L Schmid; Beat Thürlimann; M Müller; H J Senn
Recombinant human granulocyte-macrophage colony-stimulating factor for the intensification of cytostatic treatment in advanced cancer.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 1991;121():173-81.
1991: L Schmid; M Jeschko; Clive Wilder-Smith; U Schafroth; Beat Thürlimann; A Pedrazzini; H Senn
Ceftriaxone and amikacin versus ceftazidime and amikacin in febrile granulocytopenia.
Chemotherapy 1991;37(5):346-52.
1990: Beat Thürlimann; H J Senn; W F Jungi
Anthracycline-carboplatin combination in metastatic breast cancer.
Journal of cancer research and clinical oncology 1990;116(1):13-4.